

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Results from the COMFORT-I and COMFORT-II studies evaluating ruxolitinib versus placebo or best available therapy for patients with intermediate-2 or high-risk MF demonstrated \_\_\_\_\_ in favor of ruxolitinib.**
  - An improvement in splenomegaly
  - An improvement in disease-related symptoms
  - An improvement in overall survival
  - All of the above**
  - Both a and b
- 2. Ruxolitinib may be associated with which of the following side effects when administered to patients with MF?**
  - Anemia
  - Infections
  - Thrombocytopenia
  - All of the above**
- 3. Which of the following is true about the JAKARTA-2 study evaluating fedratinib in patients with MF previously treated with ruxolitinib?**
  - It was a randomized Phase III study
  - It showed an improvement in splenomegaly with fedratinib
  - It was terminated because of concerns about Wernicke encephalopathy
  - All of the above
  - Both a and b
  - Both b and c**
- 4. The PERSIST-2 study evaluating pacritinib versus best available therapy, including ruxolitinib, demonstrated this JAK2 inhibitor was effective and safe in patients with myelofibrosis and thrombocytopenia.**
  - True**
  - False
- 5. Which of the following is true regarding fedratinib in the treatment of myelofibrosis?**
  - It is a JAK2 inhibitor
  - It may cause gastrointestinal side effects
  - It is administered on a twice-daily schedule
  - All of the above
  - Both a and b**